Evidence map›Paper›PMID 33956129›Full record

ArticleJAMA network open2021

Prevalence of Medical Cannabis Use and Associated Health Conditions Documented in Electronic Health Records Among Primary Care Patients in Washington State.

Theresa E Matson, David S Carrell, Jennifer F Bobb, David J Cronkite, Malia M Oliver, Casey Luce, Udi E Ghitza, Clarissa W Hsu, Cynthia I Campbell, Kendall C Browne and 4 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Observational
  13. Is it time for a cannabis harm reduction approach? Commentary on Sherman et al. (2022) and Borodovsky et al. (2022).Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Theresa E MatsonKaiser Permanente Washington Health Research Institute, Seattle.
David S CarrellKaiser Permanente Washington Health Research Institute, Seattle.
Jennifer F BobbKaiser Permanente Washington Health Research Institute, Seattle.
David J CronkiteKaiser Permanente Washington Health Research Institute, Seattle.
Malia M OliverKaiser Permanente Washington Health Research Institute, Seattle.
Casey LuceKaiser Permanente Washington Health Research Institute, Seattle.
Udi E GhitzaCenter for the Clinical Trials Network, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
Clarissa W HsuKaiser Permanente Washington Health Research Institute, Seattle.
Cynthia I CampbellDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Kendall C BrowneCenter of Excellence in Substance Addiction Treatment and Education, Veteran Affairs Puget Sound Health Care System, Seattle, Washington.
Ingrid A BinswangerKaiser Permanente Colorado Institute for Health Research and Colorado Permanente Medical Group, Denver.
Andrew J SaxonCenter of Excellence in Substance Addiction Treatment and Education, Veteran Affairs Puget Sound Health Care System, Seattle, Washington.
Katharine A BradleyKaiser Permanente Washington Health Research Institute, Seattle.
Gwen T LaphamKaiser Permanente Washington Health Research Institute, Seattle.
Kaiser Permanente Washington Health Research Institute · USCenter for Excellence in Education · USKaiser Permanente · USNational Institutes of Health · USUniversity of Washington · US

Funding

Project-002UG1DA040314 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Ingrid A Binswanger, CYNTHIA I CAMPBELL · 2015 to 2026
$34.9M
CATALyST: Consortium for Applied Training to Advance the Learning health system with Scholars/TraineesK12HS026369 · AHRQ · KAISER FOUNDATION RESEARCH INSTITUTE · PI LOZANO, PAULA, RALSTON, JAMES D. · 2018 to 2022
$3.5M
Training Clinicians in Implementation Research to Improve Alcohol-related CareK24AA022128 · NIAAA · KAISER FOUNDATION RESEARCH INSTITUTE · PI BRADLEY, KATHARINE ANTHONY · 2016 to 2020
$876k
AHRQ HHS K12 HS026369NIAAA NIH HHS K24 AA022128NIDA NIH HHS UG1 DA040314
6 · The paper itself

Abstract

Importance: Many people use cannabis for medical reasons despite limited evidence of therapeutic benefit and potential risks. Little is known about medical practitioners' documentation of medical cannabis use or clinical characteristics of patients with documented medical cannabis use. Objectives: To estimate the prevalence of past-year medical cannabis use documented in electronic health records (EHRs) and to describe patients with EHR-documented medical cannabis use, EHR-documented cannabis use without evidence of medical use (other cannabis use), and no EHR-documented cannabis use. Design, Setting, and Participants: This cross-sectional study assessed adult primary care patients who completed a cannabis screen during a visit between November 1, 2017, and October 31, 2018, at a large health system that conducts routine cannabis screening in a US state with legal medical and recreational cannabis use. Exposures: Three mutually exclusive categories of EHR-documented cannabis use (medical, other, and no use) based on practitioner documentation of medical cannabis use in the EHR and patient report of past-year cannabis use at screening. Main Outcomes and Measures: Health conditions for which cannabis use has potential benefits or risks were defined based on National Academies of Sciences, Engineering, and Medicine's review. The adjusted prevalence of conditions diagnosed in the prior year were estimated across 3 categories of EHR-documented cannabis use with logistic regression. Results: A total of 185 565 patients (mean [SD] age, 52.0 [18.1] years; 59% female, 73% White, 94% non-Hispanic, and 61% commercially insured) were screened for cannabis use in a primary care visit during the study period. Among these patients, 3551 (2%) had EHR-documented medical cannabis use, 36 599 (20%) had EHR-documented other cannabis use, and 145 415 (78%) had no documented cannabis use. Patients with medical cannabis use had a higher prevalence of health conditions for which cannabis has potential benefits (49.8%; 95% CI, 48.3%-51.3%) compared with patients with other cannabis use (39.9%; 95% CI, 39.4%-40.3%) or no cannabis use (40.0%; 95% CI, 39.8%-40.2%). In addition, patients with medical cannabis use had a higher prevalence of health conditions for which cannabis has potential risks (60.7%; 95% CI, 59.0%-62.3%) compared with patients with other cannabis use (50.5%; 95% CI, 50.0%-51.0%) or no cannabis use (42.7%; 95% CI, 42.4%-42.9%). Conclusions and Relevance: In this cross-sectional study, primary care patients with documented medical cannabis use had a high prevalence of health conditions for which cannabis use has potential benefits, yet a higher prevalence of conditions with potential risks from cannabis use. These findings suggest that practitioners should be prepared to discuss potential risks and benefits of cannabis use with patients.

Indexed as

AdolescentAdultAgedCross-Sectional StudiesElectronic Health RecordsFemaleHumansMaleMedical MarijuanaMiddle AgedPrimary Health CareRisk AssessmentTreatment OutcomeWashingtonYoung AdultMedical Marijuana

Identifiers

PMID33956129
PMCPMC8103224
OpenAlexW3158248340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.